Extended-release fluvoxamine and improvements in quality of life in patients with obsessive-compulsive disorder

Koran, Lorrin M.; Bromberg, Daniel J.; Hornfeldt, Carl S.; Shepski, John C.; Wang, Shirley; Hollander, Eric

doi:10.1016/j.comppsych.2009.10.001

Cited by 39 publications

(46 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In RCT discontinuation studies, mirtazapine [748] and clomipramine [821] have demonstrated continued improvement compared with placebo over approximately six to 12 months. Additional data support the long-term efficacy of fluoxetine, fluvoxamine XR, and sertraline over six to 24 months [710,822-824]. …”

Section: Obsessive-compulsive Disordermentioning

confidence: 96%

Canadian clinical practice guidelines for the management of anxiety, posttraumatic stress and obsessive-compulsive disorders

et al. 2014

View full text Add to dashboard Cite

BackgroundAnxiety and related disorders are among the most common mental disorders, with lifetime prevalence reportedly as high as 31%. Unfortunately, anxiety disorders are under-diagnosed and under-treated.MethodsThese guidelines were developed by Canadian experts in anxiety and related disorders through a consensus process. Data on the epidemiology, diagnosis, and treatment (psychological and pharmacological) were obtained through MEDLINE, PsycINFO, and manual searches (1980–2012). Treatment strategies were rated on strength of evidence, and a clinical recommendation for each intervention was made, based on global impression of efficacy, effectiveness, and side effects, using a modified version of the periodic health examination guidelines.ResultsThese guidelines are presented in 10 sections, including an introduction, principles of diagnosis and management, six sections (Sections 3 through 8) on the specific anxiety-related disorders (panic disorder, agoraphobia, specific phobia, social anxiety disorder, generalized anxiety disorder, obsessive-compulsive disorder, and posttraumatic stress disorder), and two additional sections on special populations (children/adolescents, pregnant/lactating women, and the elderly) and clinical issues in patients with comorbid conditions.ConclusionsAnxiety and related disorders are very common in clinical practice, and frequently comorbid with other psychiatric and medical conditions. Optimal management requires a good understanding of the efficacy and side effect profiles of pharmacological and psychological treatments.

show abstract

Section: Obsessive-compulsive Disordermentioning

confidence: 96%

Canadian clinical practice guidelines for the management of anxiety, posttraumatic stress and obsessive-compulsive disorders

et al. 2014

View full text Add to dashboard Cite

show abstract

“…Hollander et al [10] reported that escitalopram and paroxetine were significantly superior to placebo in improving the QoL in most domains of the SF-36. However, another randomized placebo-controlled study by Koran et al [15] found that fluvoxamine was not superior to placebo in improving the QoL.…”

Section: Introductionmentioning

confidence: 99%

Quality of life changes following inpatient and outpatient treatment in obsessive-compulsive disorder: a study with 12 months follow-up

et al. 2013

View full text Add to dashboard Cite

BackgroundQuality of life (QoL) is increasingly recognized as a critical outcome parameter in mental health studies. The aim of this study was to investigate different domains of the QoL in persons with obsessive-compulsive disorder (OCD) before and after a multimodal, disorder-specific in- and outpatient treatment.MethodsData of 73 persons with OCD treated in an inpatient setting followed by outpatient treatment were analyzed. The World Health Organization Quality of Life abbreviated (a multidimensional measure of the QoL) and the Beck Depression Inventory were administered prior to (baseline) and 12 months after the inpatient treatment (follow-up).ResultsAt baseline, participants reported a significantly diminished psychological, social, physical, and global QoL compared to the German general population. Environmental QoL was not impaired in the present sample. The QoL was significantly improved at follow-up, except for social QoL, but remained below norm values. The QoL improvement was predicted by improvements of depressive symptoms.ConclusionsThe results indicate that persons with OCD suffer from a very low QoL. The QoL was significantly improved after 12 months of intensive state-of-the-art treatment. However, the QoL indices remained considerably lower than population norm values, indicating the need for additional research into novel treatment options for persons with OCD.

show abstract

“…These disorders are associated with high personal and economic costs (DuPont et al, 1996) and low quality of life (Cramer, Torgersen & Kringlen, 2005; Mendlowicz, & Stein, 2000; Olatunji, Cisler, & Tolin, 2007; Rapaport, Clary, Fayyad, & Endicott, 2005). For example, it has been reported that obsessive-compulsive disorder (Koran, Thienemann, & Davenport 1996), panic disorder (Candilis et al,1999; Rubin et al, 2000) and social anxiety disorder (Safren, Heimberg, Brown, & Holle, 1996–1997; Wittchen & Beloch, 1996) have substantially poorer quality of life than community samples. In some cases, anxiety disorders have an even greater impact on quality of life than chronic medical disorders (Spitzer et al, 1995; Sherbourne, Wells, & Judd, 1996).…”

mentioning

confidence: 99%

Effect of cognitive-behavioral therapy for anxiety disorders on quality of life: A meta-analysis.

Hofmann¹,

Wu²,

Boettcher³

2014

Journal of Consulting and Clinical Psychology

152

View full text Add to dashboard Cite

OBJECTIVE Although cognitive-behavioral therapy is effective for treating anxiety disorders, little is known about its effect on quality of life. To conduct a meta-analysis of cognitive-behavioral therapy for anxiety disorders on quality of life, we searched for relevant studies in PubMed, PsycINFO and the Cochrane Library, and conducted manual searches. METHOD The search identified 44 studies that included 59 CBT trials, totaling 3,326 participants receiving cognitive-behavioral therapy for anxiety disorders. We estimated the controlled and within-group random effects of the treatment changes on quality of life. RESULTS The pre-post within-group and controlled effect sizes were moderately strong, Hedges’ g = 0.54 and Hedges’ g = 0.56, respectively. Improvements were greater for physical and psychological domains of quality of life than for environmental and social domains. The overall effect sizes decreased with publication year and increased with treatment duration. Face-to-face treatments delivered individually and in groups produced significantly higher effect sizes than internet-delivered treatments. CONCLUSION Cognitive-behavioral therapy for anxiety disorders is moderately effective for improving quality of life, especially in physical and psychological domains. Internet-delivered treatments are less effective in improving quality of life than face-to-face treatments.

show abstract

Extended-release fluvoxamine and improvements in quality of life in patients with obsessive-compulsive disorder

Cited by 39 publications

References 24 publications

Canadian clinical practice guidelines for the management of anxiety, posttraumatic stress and obsessive-compulsive disorders

Canadian clinical practice guidelines for the management of anxiety, posttraumatic stress and obsessive-compulsive disorders

Quality of life changes following inpatient and outpatient treatment in obsessive-compulsive disorder: a study with 12 months follow-up

Effect of cognitive-behavioral therapy for anxiety disorders on quality of life: A meta-analysis.

Contact Info

Product

Resources

About